Development of a measurement kit for serum glycoprotein markers we identified as useful for early detection of ovarian clear cell carcinoma.

2023 Fiscal Year Final Research Report

• Project/Area Number: 21K09457
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 56040:Obstetrics and gynecology-related
• Research Institution: Tokai University
• Principal Investigator: Ikeda Masae 東海大学, 医学部, 准教授 (20365993)
• Co-Investigator(Kenkyū-buntansha): 三上 幹男 東海大学, 医学部, 教授 (30190606)
• Project Period (FY): 2021-04-01 – 2024-03-31
• Keywords: 卵巣癌 / 子宮内膜症 / 卵巣内膜症性嚢胞 / 卵巣明細胞腺癌 / 血清腫瘍マーカー

Outline of Final Research Achievements

In Japan, the number of ovarian clear cell carcinoma (CCC), in which endometriosis (EM) is a precancerous lesion, is increasing in young women. We have identified the FS-C4BP (patented), which discriminates EM and CCC more significantly than CA125 and have developed a measurement kit. We have also initiated studies of developing the measurement kit of WFA reactive Ceruloplasmin (Anal Chem. PMID: 35044763).

Free Research Field

婦人科腫瘍/卵巣癌/腫瘍マーカー

Academic Significance and Societal Importance of the Research Achievements

EMは若年発症が多く挙児希望が多いために、妊孕性温存療法で長期間経過観察していくことが多い。経過観察は、画像診断とCA125で行なわれるが、CCC早期検出にまで至っていない。この状況で、CA125よりも有用性が認められるFS-C4BPの測定を行い、今後WFA-CPの測定も開始する。今後、この二つのマーカーを用いてEMのCCCへの移行の早期発見の可能性を期待しうる。